TFMT，5MG，SML3760-5MG，Sigma

Biochem/physiol Actions

SAM-binding pocket-targeting methyltransferase MTr1 inhibitor with anti-influenza efficacy in vitro and in vivo.
Trifluoromethyl-tubercidin (TFMT) is a SAM-binding pocket-targeting methyltransferase (MTase) MTr1 inhibitor that impedes the maturation of host cap RNAs and their binding with influenza viral polymerase. TFMT selectively inhibits influenza A&B (IAV & IBV), but not Hazara virus (HAZV) or soft tick bunyavirus (STBV), replication in epithelial cultures (IAV IC50 = 300 nM/human A549, 7.7 μM/murine LA-4) with little toxicity (up to 1 mM; A549 cells). TFMT suppresses IAV replication in mice in vivo (2 mg/kg intranasally on day 0 and day 1 of IAV infection) and synergizes with anti-influenza drugs baloxavir marboxil (BXM; endonuclease inhibitor) and oseltamivir (neuraminidase inhibitor).